What does Eisai do?
EISAI is a global pharmaceutical company that focuses on the research, development, and commercialization of innovative medicines. The company specializes in areas such as neurology and oncology, aiming to address unmet medical needs. EISAI is committed to improving the quality of life for patients through its advanced healthcare solutions.
- Signals
-
ProfitableProfitable € 216K
The company reported a positive net result in the latest financial year.
Strong equityStrong equity € 4.61MStrong equity provides a buffer against setbacks.
Low riskLow risk 65.1%Good solvency (> 30%) points to long-term financial stability.
Good liquidityGood liquidity 2.85A healthy current ratio (≥ 1.5): enough current assets to cover short-term debt.
Positive cashflowPositive cashflow € 224KPositive operating cash flow in the latest financial year.
Positive EBITDAPositive EBITDA € 308KPositive EBITDA: operating activities are profitable.
High turnoverHigh turnover € 7.59MSubstantial turnover in the latest financial year.
Healthy social debtHealthy social debt 22.2%Social debts stay manageable relative to personnel costs.
Financial ratios
|
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2026
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2025
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2024
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2023
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
|---|---|---|---|---|
|
€
7.59M
|
€
10.36M
|
|
|
|
|
€
308K
|
€
487K
|
€
713K
|
€
519K
|
|
|
€
216K
|
€
353K
|
€
515K
|
€
354K
|
|
|
€
4.61M
|
€
4.39M
|
€
4.04M
|
€
3.52M
|
|
|
65.06%
|
60.6%
|
44.67%
|
43.39%
|
|
|
€
2.48M
|
€
2.85M
|
€
5.00M
|
€
4.59M
|
|
|
€
117K
|
€
630K
|
€
3.50M
|
€
2.90M
|
|
|
12.60
|
12.60
|
13.40
|
13.60
|
Publications 38
All publications- Ontslagen - Benoemingen 07/08/2023
- Statuts (Traduction, Coordination, Autres Modifications, ) 18/07/2023
- Ontslagen - Benoemingen 30/09/2022
- Ontslagen - Benoemingen 22/06/2022
- Ontslagen - Benoemingen 26/10/2020
Frequently asked questions
Answers to the most common questions about Eisai, based on official government data and the filed annual accounts.
What is the VAT number of Eisai?
The VAT number of Eisai is BE0891.958.055.
How many employees work at Eisai?
In 2026, Eisai employed 12.60 full-time equivalents (FTE).
When was Eisai established?
Eisai was founded in 10-09-2007.
What is the official address of Eisai?
The official address of Eisai is Brusselsestraat 190 Leuven 3000.
What is the legal form of Eisai?
The juridical form of Eisai is Public limited company (NV/SA).
What is the annual revenue of Eisai?
The revenue of Eisai for the 2026 financial year was €7,590,065.
What does Eisai do?
EISAI is a global pharmaceutical company that focuses on the research, development, and commercialization of innovative medicines. The company specializes in areas such as neurology and oncology, aiming to address unmet medical needs. EISAI is committed to improving the quality of life for patients through its advanced healthcare solutions.
Is Eisai a reliable company?
Eisai is a registered Rechtspersoon with company number 0891.958.055 and can be verified through the official CBE database.
What is the credit limit of Eisai?
The estimated credit limit of Eisai is €923,259.
Is Eisai still active?
Eisai currently has the status "Normal situation" and is active.